Milrinone — Discount Pricing
Milrinone is not confirmed for no-additional-cost pricing. Discount pricing may be available; confirm the price with the dispensing pharmacy.
Milrinone Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Discount pricing may be available |
| Typical Retail | $31.00 |
Discount pricing may be available; confirm the price with the dispensing pharmacy.
About Milrinone
Milrinone is a prescription medication. Ask your doctor if Milrinone is right for you.
How to Check Milrinone Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
Milrinone at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Other medications in Heart & Cardiovascular
About Milrinone
Milrinone is a powerful medication often used in critical care settings to support the hearts of patients suffering from acute decompensated heart failure. While essential for many, its cost can be a concern. TheDrugClub is dedicated to helping members access vital prescriptions like milrinone at more affordable prices, ensuring you can focus on health, not high costs.
What Milrinone Treats
Milrinone is a medication primarily used for the short-term treatment of acute decompensated heart failure. This is a severe condition where the heart suddenly can't pump enough blood to meet the body's needs. Patients requiring milrinone are
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.
What Milrinone is approved for (FDA label)
Milrinone Lactate Injection, USP is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. Patients receiving milrinone lactate should be observed closely with appropriate electrocardiographic equipment. The facility for immediate treatment of potential cardiac events, which may include life threatening ventricular arrhythmias, must be available. The majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. There is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours.
Source: Read the full FDA label on DailyMed. Label effective date: July 27, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Milrinone (FDA label)
Cardiovascular Effects In patients receiving milrinone in Phase II and III clinical trials, ventricular arrhythmias were reported in 12.1%: Ventricular ectopic activity, 8.5%; nonsustained ventricular tachycardia, 2.8%; sustained ventricular tachycardia, 1% and ventricular fibrillation, 0.2% (2 patients experienced more than one type of arrhythmia). Holter recordings demonstrated that in some patients injection of milrinone increased ventricular ectopy, including nonsustained ventricular tachycardia. Life-threatening arrhythmias were infrequent and when present have been associated with certain underlying factors such as preexisting arrhythmias, metabolic abnormalities (e.g. hypokalemia), abnormal digoxin levels and catheter insertion. Milrinone was not shown to be arrhythmogenic in an electrophysiology study. Supraventricular arrhythmias were reported in 3.8% of the patients receiving milrinone.
Source: FDA prescribing information (DailyMed). Set ID: 07dddead-22ed-004c-e063-6294a90a76fc. SPL document ID: 579eba00-979d-93a1-e063-6294a90abb9d. Label effective date: July 27, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Milrinone (FDA label)
Milrinone Lactate Injection, USP is contraindicated in patients who are hypersensitive to it.
Source: FDA prescribing information (DailyMed). Set ID: 07dddead-22ed-004c-e063-6294a90a76fc. SPL document ID: 579eba00-979d-93a1-e063-6294a90abb9d. Label effective date: July 27, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.